U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07301229) titled 'A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer' on Nov. 25.
Brief Summary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)
Study Start Date: Dec. 29
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention:
DRUG: HLX43 DOSE 1 (2.5 mg/kg)
HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
DRUG: HLX...